Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-09-04)
CHF 12.02-2.91%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

star star star star star
4.50 4 votes No rating yet
NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

39.3%1Y
101%3Y
479%5Y

Performance

56.4%1Y
64.9%3Y
73.6%5Y

Volatility

Market cap

297 M

Market cap (USD)

Daily traded volume (Shares)

47,501

Daily traded volume (Shares)

1 day high/low

8.99 / 8.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

4 votes
Performance:
starstarstarstarstar
3.25
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.75
Uwe K.
Switzerland, 30 Mar 2025
star star star star star
Könnte interessant sein.
Caterina F
Switzerland, 26 Mar 2025
star star star star star
Worth paying attention to
Markus Fässler
Switzerland, 05 Feb 2024
star star star star star
Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Icon PLC
Icon PLC Icon PLC Valor: 1017575
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.78%USD 164.85
Ramsay Generale de Sante SA
Ramsay Generale de Sante SA Ramsay Generale de Sante SA Valor: 1247709
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.73%EUR 10.70
IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.42%USD 267.77
Robertet SA
Robertet SA Robertet SA Valor: 510354
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.14%EUR 797.00
H. Lundbeck A/S
H. Lundbeck A/S H. Lundbeck A/S Valor: 119252584
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.23%DKK 43.85
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc Madrigal Pharmaceuticals Inc Valor: 33395434
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.28%USD 541.08
Cencora Inc
Cencora Inc Cencora Inc Valor: 1212868
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.86%USD 330.95
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.13%USD 86.35
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc Zimmer Biomet Holdings Inc Valor: 1262932
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.86%USD 98.07
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.22%USD 80.67